Last updated on May 2018

Strategic Screening for Infectious Diseases (Tuberculosis HIV HBV HCV) Amongst Migrants in France


Brief description of study

To evaluate the efficacy of a new screening for infectious diseases: tuberculosis, HIV, HBV and HCV, based on risk factors questionnaires (TB screen for tuberculosis and TROD screen for HIV and hepatitis) amongst a population of legal migrants during their mandatory medical check-up. This study aims for a global improvement of screening and care for migrants.

Detailed Study Description

In France, the prevalence of infectious diseases such as tuberculosis, HIV/HBV/HCV is high amongst migrants originating from certain countries, hence the official guidelines recommending targeted testing. The rapid testing devices (TROD) give immediate results and reduce missed opportunities. However their use is not yet widespread and migrant populations remain insufficiently tested. Regarding the UNAIDS 90-90-90 goal, France is failing the screening part of the treatment cascade, while 90% of patients are treated and have undetectable viral load. Risk scores based on the best known risk factors for these infections (HIV/HBV/HCV) have previously been developed. They have helped build a pilot of a new unique questionnaire: TROD screen. An electronic survey, called TB screen, was designed to screen for tuberculosis amongst asylum seekers in Switzerland and validated. This survey enables to detect signs of active tuberculosis and may replace the use of pulmonary radiography, thus reducing exposure to X-rays.

It is a prospective multi-centric observational study validating screening tests for HIV/HBV/HCV in two phases:

  • Phase 1: a risk score will be validated, including a qualitative study analyzing its acceptability
  • Phase 2: its performance will be compared with that of a screening targeted based on the country of origin The phase 1 and phase 2 will include respectively 10.000 and 5000 participants.

For tuberculosis, the efficacy of the improved version of TB screen will be compared with a systematic radiography.

Participation to this study will be voluntary and independent from the delivery of a residence permit. Participants will be informed of it and will systematically receive information about prevention of those infectious diseases.

Clinical Study Identifier: NCT02959684

Contact Investigators or Research Sites near you

Start Over

Frédérique Thonon

OFII Bordeaux
Bordeaux, France
  Connect »

Sabrina Lakhdari

OFII Cergy
Cergy, France
  Connect »

Martin Duracinsky, MD, PhD

OFII Clermont-Ferrand
Clermont-Ferrand, France
  Connect »

Frédérique Thonon

OFII Grenoble
Grenoble, France
  Connect »

Sabrina Lakhdari

OFII Lille
Lille, France
  Connect »

Frédérique Thonon

OFII Lyon
Lyon, France
  Connect »

Frédérique Thonon

OFII Marseille
Marseille, France
  Connect »

Frédérique Thonon

OFII Melun
Melun, France
  Connect »

Frédérique Thonon

OFII Montpellier
Montpellier, France
  Connect »

Frédérique Thonon

OFII Nantes
Nantes, France
  Connect »

Frédérique Thonon

OFII Nice
Nice, France
  Connect »

Frédérique Thonon

OFII Reims
Reims, France
  Connect »

Frédérique Thonon

OFII Rennes
Rennes, France
  Connect »

Sabrina Lakhdari

OFII Rouen
Rouen, France
  Connect »

Frédérique Thonon

OFII Toulouse
Toulouse, France
  Connect »

Sabrina Lakhdari

OFII Metz
Metz, France
  Connect »

Frédérique Thonon

OFII Montrouge
Montrouge, France
  Connect »

Frédérique Thonon

OFII Orl ans
Orléans, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.